• Explore /
  • Poster
  • / Quizartinib (QUIZ) with decitabine (DAC) and venetoclax (VEN) is active in patients (pts) with FLT3-ITD mutated acute myeloid leukemia (AML): A phase I/II clinical trial.

Quizartinib (QUIZ) with decitabine (DAC) and venetoclax (VEN) is active in patients (pts) with FLT3-ITD mutated acute myeloid leukemia (AML): A phase I/II clinical trial.

Abstract Poster

Authors

null

Musa Yilmaz

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Musa Yilmaz , Muharrem Muftuoglu , Hagop M. Kantarjian , Courtney Denton Dinardo , Tapan M. Kadia , Marina Konopleva , Gautam Borthakur , Naveen Pemmaraju , Nicholas James Short , Yesid Alvarado Valero , Abhishek Maiti , Lucia Masarova , Guillermo Montalban Bravo , Sanam Loghavi , Steven Mitchell Kornblau , Elias Jabbour , Guillermo Garcia-Manero , Farhad Ravandi , Michael Andreeff , Naval Guastad Daver

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT03661307

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7036)

DOI

10.1200/JCO.2022.40.16_suppl.7036

Abstract #

7036

Poster Bd #

267

Abstract Disclosures

Similar Posters

First Author: Farhad Ravandi

First Author: Guillermo Garcia-Manero

First Author: Matthew Newman

Poster

2020 ASCO Virtual Scientific Program

Ten-day decitabine with venetoclax (DEC10-VEN) in AML and high-risk (HR) MDS.

Ten-day decitabine with venetoclax (DEC10-VEN) in AML and high-risk (HR) MDS.

First Author: Abhishek Maiti